TR200103216T2 - Pirimidinon bileşimleri - Google Patents

Pirimidinon bileşimleri

Info

Publication number
TR200103216T2
TR200103216T2 TR2001/03216T TR200103216T TR200103216T2 TR 200103216 T2 TR200103216 T2 TR 200103216T2 TR 2001/03216 T TR2001/03216 T TR 2001/03216T TR 200103216 T TR200103216 T TR 200103216T TR 200103216 T2 TR200103216 T2 TR 200103216T2
Authority
TR
Turkey
Prior art keywords
pyrimidinone
compositions
atherosclerosis
inhibitors
therapy
Prior art date
Application number
TR2001/03216T
Other languages
English (en)
Inventor
Edward Fenwick Ashley
Mary Bernadette Hickey Deirdre
John Ife Robert
Andrew Leach Colin
Leo Pinto Ivan
Allan Smith Stephen
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9910048A external-priority patent/GB9910048D0/en
Priority claimed from GB0002096A external-priority patent/GB0002096D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of TR200103216T2 publication Critical patent/TR200103216T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Formü (i)pirimidinon bilesimleri Lp-PLA2 enziminin inhibitörleri olup, terapide, özellikle ateroskleroz tedavisinde kullanilir.
TR2001/03216T 1999-05-01 2000-04-25 Pirimidinon bileşimleri TR200103216T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9910048A GB9910048D0 (en) 1999-05-01 1999-05-01 Novel compounds
GB0002096A GB0002096D0 (en) 2000-01-28 2000-01-28 Novel compounds

Publications (1)

Publication Number Publication Date
TR200103216T2 true TR200103216T2 (tr) 2002-04-22

Family

ID=26243514

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03216T TR200103216T2 (tr) 1999-05-01 2000-04-25 Pirimidinon bileşimleri

Country Status (29)

Country Link
US (2) US6953803B1 (tr)
EP (2) EP1479671B1 (tr)
JP (1) JP2002543190A (tr)
KR (1) KR20020012200A (tr)
CN (1) CN1286822C (tr)
AR (1) AR023777A1 (tr)
AT (2) ATE432265T1 (tr)
AU (1) AU766003B2 (tr)
BR (1) BR0010220A (tr)
CA (1) CA2371671A1 (tr)
CO (1) CO5170521A1 (tr)
CZ (1) CZ20013904A3 (tr)
DE (2) DE60016397T2 (tr)
DK (1) DK1175408T3 (tr)
ES (1) ES2233361T3 (tr)
HK (1) HK1044757B (tr)
HU (1) HUP0201122A3 (tr)
IL (1) IL146210A0 (tr)
MX (1) MXPA01011186A (tr)
MY (1) MY136037A (tr)
NO (1) NO20015329D0 (tr)
NZ (1) NZ515137A (tr)
PE (1) PE20010070A1 (tr)
PL (1) PL351690A1 (tr)
PT (1) PT1175408E (tr)
SI (1) SI1175408T1 (tr)
TR (1) TR200103216T2 (tr)
UY (1) UY26132A1 (tr)
WO (1) WO2000066567A1 (tr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013904A3 (cs) * 1999-05-01 2002-04-17 Smithkline Beecham Plc Pyrimidinonové sloučeniny
AU2001235466B2 (en) 2000-02-16 2004-04-22 Glaxo Group Limited Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
WO2005003118A1 (de) * 2003-07-02 2005-01-13 Bayer Healthcare Ag Amid-substituierte 1,2,4-triazin-5 (2h)-one zur behandlung von chronisch inflammatorischen krankheiten
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
EP2290094A1 (en) 2004-04-16 2011-03-02 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
DE102004061009A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061006A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Benzylthio-1,2,4-triazin-5(2H)-one
CN1954826A (zh) * 2005-10-26 2007-05-02 上海生物芯片有限公司 银杏叶提取物在降低胆固醇方面的用途
KR101461659B1 (ko) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
WO2008141176A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
TW201209043A (en) 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes
EP2649053B1 (en) 2010-12-06 2015-11-04 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
BR112014001634A2 (pt) 2011-07-27 2017-02-14 Glaxo Group Ltd compostos bicíclicos de pirimidona
EP2739627A4 (en) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
UA108713C2 (xx) * 2011-11-11 2015-05-25 2-тіопіримідинони
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
MX2015009633A (es) 2013-01-25 2015-11-30 Glaxosmithkline Ip Dev Ltd Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona.
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9552473B2 (en) 2014-05-14 2017-01-24 Microsoft Technology Licensing, Llc Claiming data from a virtual whiteboard
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
PE20230092A1 (es) 2019-11-09 2023-01-16 Shanghai Simr Biotechnology Co Ltd Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceuticas y uso del mismo
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582527A (en) * 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
WO1999024420A1 (en) * 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
WO2000010980A1 (en) * 1998-08-21 2000-03-02 Smithkline Beecham Plc Pyrimidinone derivatives for the treatment of atherosclerosis
CZ20013904A3 (cs) * 1999-05-01 2002-04-17 Smithkline Beecham Plc Pyrimidinonové sloučeniny

Also Published As

Publication number Publication date
AR023777A1 (es) 2002-09-04
MY136037A (en) 2008-08-29
EP1175408B1 (en) 2004-12-01
PT1175408E (pt) 2005-04-29
CN1286822C (zh) 2006-11-29
HK1044757B (zh) 2005-07-08
HUP0201122A2 (en) 2002-08-28
AU766003B2 (en) 2003-10-09
PL351690A1 (en) 2003-06-02
PE20010070A1 (es) 2001-03-10
US6953803B1 (en) 2005-10-11
NO20015329L (no) 2001-10-31
DE60016397D1 (de) 2005-01-05
CZ20013904A3 (cs) 2002-04-17
DE60042286D1 (de) 2009-07-09
UY26132A1 (es) 2000-12-29
NO20015329D0 (no) 2001-10-31
JP2002543190A (ja) 2002-12-17
EP1479671A1 (en) 2004-11-24
AU4120300A (en) 2000-11-17
MXPA01011186A (es) 2002-08-12
DE60016397T2 (de) 2005-12-01
BR0010220A (pt) 2002-05-14
HUP0201122A3 (en) 2003-11-28
EP1479671B1 (en) 2009-05-27
DK1175408T3 (da) 2005-04-11
CA2371671A1 (en) 2000-11-09
ES2233361T3 (es) 2005-06-16
EP1175408A1 (en) 2002-01-30
KR20020012200A (ko) 2002-02-15
NZ515137A (en) 2003-10-31
CN1358175A (zh) 2002-07-10
SI1175408T1 (en) 2005-04-30
HK1044757A1 (en) 2002-11-01
CO5170521A1 (es) 2002-06-27
IL146210A0 (en) 2002-07-25
US7115616B2 (en) 2006-10-03
ATE432265T1 (de) 2009-06-15
US20040167142A1 (en) 2004-08-26
WO2000066567A1 (en) 2000-11-09
ATE283845T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
TR200103216T2 (tr) Pirimidinon bileşimleri
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
BR9707233A (pt) Fenantridinas
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
TR200103493T2 (tr) Metaloproteaz önleyicileri
TR199901604T2 (tr) Tedavide yararli kinolin ve kinazolin bilesikleri.
NO20013554L (no) Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
PT998460E (pt) Novos derivados de tetrazole
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
PT1147103E (pt) Fenantridina-n-oxidos com actividade inibitoria de pde-iv
PT1147088E (pt) 6-arilfenantridinas com actividade inibitoria da pde-iv
YU68900A (sh) Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DE60124030D1 (de) Behandlung von Pansenacidose mit Amylasehemmern
TR200002027T2 (tr) Bir emayeleme tesisinden gelen dolaşım suyunun muamele işlemi.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ATE269313T1 (de) Tryptase-inhibitoren
PT1244614E (pt) Inibidores de triptase
IL139144A0 (en) Mycobacterial inhibitors
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
PT937075E (pt) Novas imidazo- e oxazolo-piridinas como inibidores da fosfodiesterese